Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer

被引：1
|
作者：
Mardani, Mahta
Noordeen, Suleyman
Clifton, Katherine
Ma, Cynthia
Luo, Jingqin
Xi, Jing
Bagegni, Nusayba
Ademuyiwa, Foluso
Suresh, Rama
Frith, Ashley
Davis, Andrew
Bose, Ron
Peterson, Lindsay
Thomas, Shana
Tao, Yu
Kobayashi, Takayuki
Xiang, Jingyu
Xu, Yalin
Su, Xinming
Weilbaecher, Katherine
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-05-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-05-05
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
    Loibl, Sibylle
    Furlanetto, Jenny
    BREAST, 2022, 62 : S70 - S79
  • [32] Improving Breast Cancer Therapy With CDK4/6 Inhibitors
    Jaganathan, Hamsa
    Overstreet, Karen
    Reed, Elizabeth
    CLINICAL BREAST CANCER, 2014, 14 (06) : 379 - 380
  • [33] Predicting Response to CDK4/6 Inhibitors in Breast Cancer
    Schultz, Emily
    Hamilton, Deanna
    Wang, Jianxin
    Witkiewicz, Agnieszka
    LABORATORY INVESTIGATION, 2023, 103 (03) : S208 - S208
  • [34] CDK4/6 inhibitors in breast cancer: spotting the difference
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    NATURE MEDICINE, 2021, 27 (11) : 1868 - 1869
  • [35] CDK4/6 inhibitors in breast cancer: spotting the difference
    Jose Manuel Perez-Garcia
    Javier Cortes
    Antonio Llombart-Cussac
    Nature Medicine, 2021, 27 : 1868 - 1869
  • [36] The role of CDK4/6 inhibitors in early breast cancer
    Gil-Gil, Miguel
    Alba, Emilio
    Gavila, Joaquin
    de la Haba-Rodriguez, Juan
    Ciruelos, Eva
    Tolosa, Pablo
    Candini, Daniele
    Llombart-Cussac, Antonio
    BREAST, 2021, 58 : 160 - 169
  • [37] Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study
    Claire C. Conley
    McKenzie McIntyre
    Nicole A. Pensak
    Filipa Lynce
    Deena Graham
    Roohi Ismail-Khan
    Katherine Lopez
    Susan T. Vadaparampil
    Suzanne C. O’Neill
    Breast Cancer Research and Treatment, 2022, 192 : 385 - 399
  • [38] Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer
    Oner, Irem
    Turkel, Alper
    Anik, Hicran
    Arslan, Ulku Yalcintas
    Karacin, Cengiz
    FUTURE ONCOLOGY, 2024,
  • [39] Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study
    Conley, Claire C.
    McIntyre, McKenzie
    Pensak, Nicole A.
    Lynce, Filipa
    Graham, Deena
    Ismail-Khan, Roohi
    Lopez, Katherine
    Vadaparampil, Susan T.
    O'Neill, Suzanne C.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (02) : 385 - 399
  • [40] Immune cell populations in peripheral blood of metastatic breast cancer patients under CDK4/6 inhibitors
    Lobo-Martins, Soraia
    Corredeira, Patricia
    Alves, Patricia Borges
    Antunes, Marilia
    Rodrigues, Angela
    Quintela, Antonio
    Mansinho, Andre
    Filipe, Pedro
    Ribeiro, Leonor
    de Sousa, Rita Teixeira
    Pinto, Conceicao
    Abreu, Catarina
    Gordino, Gisela
    Ribot, Julie
    Serre, Karine
    Martins, Marta
    Cavaco, Ana
    Casimiro, Sandra
    Silva-Santos, Bruno
    Costa, Luis
    CANCER RESEARCH, 2021, 81 (04)
12345